10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics ...

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene-sequencing solutions based in the US. In a rather competitive market, TXG’s focus has been on single-cell and ...

10x Genomics, a company focused on accelerating discovery, today announced the launch of the Single Cell Mouse Immune Profiling Solution. For the first time, researchers will have the ability to ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

We offer a range of services, including single cell RNA sequencing and spatial transcriptomics. Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which ...

The Chromium platform developed by 10x Genomics is the "gold standard" in single-cell genomic analysis ... maximize the number of base pairs sequenced in the least amount of time.

In a report released today, Luke Sergott from Barclays maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target of $12.00. The company’s shares closed yesterday at ...